 Ambulatory participants with Secondary Progressive Multiple Sclerosis SPMS enrolled in the EXPAND trial BAF312 treated and placebo control participants may be enrolled in this study after the EXPAND baseline visit has occurred provided that the subject has not passed the Month 12 time point. 